AstraZeneca CEO Hopes A Post-Trump And Brexit World Won't Damage Pharma
AstraZeneca's CEO Pascal Soriot says change is inevitable for pharma after Donald Trump's election win and the UK's decision to leave the EU and that dialogue with governments will be necessary to ensure key benefits of globalization enjoyed by the sector are retained.
You may also be interested in...
Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.